Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>

• Prif Awduron: Worapong Nasomsong (Awdur), Parnrada Nulsopapon (Awdur), Dhitiwat Changpradub (Awdur), Supanun Pungcharoenkijkul (Awdur), Patomroek Hanyanunt (Awdur), Tassanawan Chatreewattanakul (Awdur), Wichai Santimaleeworagun (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: MDPI AG, 2022-04-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Carbapenem-resistant <i>Pseudomonas aeruginosa</i> (CRPA) is a hospital-acquired pathogen with a high mortality rate and limited treatment options. We investigated the activity of ceftolozane/tazobactam (C/T) and its synergistic effects with amikacin to extend the range of optimal therap...